All Outputs (15)

Patient‐reported outcomes in studies of diabetes technology: What matters (2024)
Journal Article
Liarakos, A. L., Crabtree, T. S., & Wilmot, E. G. (2024). Patient‐reported outcomes in studies of diabetes technology: What matters. Diabetes, Obesity and Metabolism, 26(S7), 59-73. https://doi.org/10.1111/dom.15858

In recent years, diabetes technologies have revolutionized the care of people with type1 diabetes (T1D). Emerging evidence suggests that people with type 2 diabetes (T2D) canexperience similar benefits from these advances in technology. While glycaem... Read More about Patient‐reported outcomes in studies of diabetes technology: What matters.

The use of technology in type 2 diabetes and prediabetes: a narrative review (2024)
Journal Article
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024). The use of technology in type 2 diabetes and prediabetes: a narrative review. Diabetologia, 67(10), 2059-2074. https://doi.org/10.1007/s00125-024-06203-7

The increasing incidence of type 2 diabetes, which represents 90% of diabetes cases globally, is a major public health concern. Improved glucose management reduces the risk of vascular complications and mortality; however, only a small proportion of... Read More about The use of technology in type 2 diabetes and prediabetes: a narrative review.

Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring (2024)
Journal Article
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2024). Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, https://doi.org/10.1177/19322968241250357

Continuous glucose monitoring (CGM) has been shown to improve glycemic control and self-monitoring, as well as to reduce the risk of hypoglycemia. Integrated CGM (iCGM) FDA-cleared systems with published performance data are established nonadjunctive... Read More about Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring.

Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis (2024)
Journal Article
Mader, J. K., Fornengo, R., Hassoun, A., Heinemann, L., Kulzer, B., Monica, M., Nguyen, T., Sieber, J., Renard, E., Reznik, Y., Rys, P., Stozek, A., & Wilmot, E. G. (2024). Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis. Diabetes Technology and Therapeutics, 26(5), 351-362. https://doi.org/10.1089/dia.2023.0491

Background: Lipohypertrophy is a common complication in patients with diabetes receiving insulin therapy. There is a lack of consensus regarding how much lipohypertrophy affects diabetes management. Our study aimed to assess the potential correlation... Read More about Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis.

Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study (2024)
Journal Article
Liarakos, A. L., Hasan, N., Crabtree, T. S. J., Leelarathna, L., Hammond, P., Hussain, S., Haq, M., Aslam, A., Gatdula, E., Gibb, F. W., Lumb, A., Bull, K., Chinnasamy, E., Carrieri, G., Williams, D. M., Choudhary, P., Ryder, R. E. J., & Wilmot, E. G. (2024). Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Research and Clinical Practice, 209, Article 111597. https://doi.org/10.1016/j.diabres.2024.111597

Aims
To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System

Methods
Anonymized clinical data were submitted to a secure web-based tool within the National Health Service networ... Read More about Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study.

Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study (2023)
Journal Article
Leelarathna, L., Sutton, C. J., Evans, M. L., Neupane, S., Rayman, G., Lumley, S., Cranston, I., Narendran, P., Krishan, A., Taxiarchi, V. P., Barnard-Kelly, K., Elliott, R. A., Burns, M., Camm, M., Thabit, H., & Wilmot, E. G. (2024). Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study. Diabetic Medicine, 41(3), Article e15249. https://doi.org/10.1111/dme.15249

Aims: The FLASH-UK trial showed lower HbA1c with intermittently scanned continuous glucose monitoring (isCGM), as compared with self monitoring of blood glucose (SMBG), in adults with type 1 diabetes and HbA1c ≥58 mmol/mol (≥7.5%). Here, we present r... Read More about Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study.

Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England (2023)
Journal Article
Elliott, R. A., Rogers, G., Evans, M. L., Neupane, S., Rayman, G., Lumley, S., Cranston, I., Narendran, P., Sutton, C. J., Taxiarchi, V. P., Burns, M., Thabit, H., Wilmot, E. G., Leelarathna, L., & FLASH–UK Trial Study Group. (2024). Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabetic Medicine, 41(3), Article e15232. https://doi.org/10.1111/dme.15232

We previously showed that intermittently scanned continuous glucose monitoring (isCGM) reduces HbA1c at 24 weeks compared with self-monitoring of blood glucose with finger pricking (SMBG) in adults with type 1 diabetes and high HbA1c levels (58-97 mm... Read More about Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England.

Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study (2023)
Journal Article
Crabtree, T. S., Griffin, T. P., Yap, Y. W., Narendran, P., Gallen, G., Furlong, N., Cranston, I., Chakera, A., Philbey, C., Karamat, M. A., Saraf, S., Kamaruddin, S., Gurnell, E., Chapman, A., Hussain, S., Elliott, J., Leelarathna, L., Ryder, R. E., Hammond, P., Lumb, A., …Lambert, P. (2023). Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study. Diabetes Care, 46(10), 1831-1838. https://doi.org/10.2337/dc23-0635

OBJECTIVE
We explored longitudinal changes associated with switching to hybrid closed loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitori... Read More about Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study.

A nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19 (2023)
Journal Article
Field, B. C. T., Ruan, Y., Várnai, K. A., Davies, J., Ryder, R. E. J., Gandhi, R., Harris, S., Nagi, D., Patel, D., Kempegowda, P., Wild, S. H., Wilmot, E. G., Khunti, K., Rea, R., Narendran, P., Edwards, A., Gelding, S., Gunganah, K., Aung, P., Banerjee, M., …Williams, D. (2023). A nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19. Diabetes, Obesity and Metabolism, 25(7), 2012-2022. https://doi.org/10.1111/dom.15076

Aims
To investigate characteristics of people hospitalized with coronavirus-disease-2019 (COVID-19) and diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), and to identify risk factors for mortality and intensive care admission... Read More about A nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19.

UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy (2023)
Journal Article
Griffin, T. P., Gallen, G., Hartnell, S., Crabtree, T., Holloway, M., Gibb, F. W., Lumb, A., Willmot, E. G., Choudhary, P., & Hussain, S. (2023). UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy. Diabetic Medicine, 41(3), Article e15078. https://doi.org/10.1111/dme.15078

This best practice guide is written with the aim of providing an overview of current hybrid closed-loop (HCL) systems in use within the United Kingdom's (UK) National Health Service (NHS) and to provide education and advice for their management on bo... Read More about UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy.

CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review (2022)
Journal Article
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023). CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review. Diabetes, Obesity and Metabolism, 25(4), 916-939. https://doi.org/10.1111/dom.14962

The National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenn... Read More about CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review.

Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19 (2022)
Journal Article
Khunti, K., Ruan, Y., Davies, J., Field, B. C., Harris, S., Kosiborod, M., Nagi, D., Narendran, P., Patel, D., Ryder, R. E., Várnai, K. A., Wild, S. H., Wilmot, E. G., Rea, R., Gandhi, R., Harris, S., Nagi, D., Ryder, R., Davies, J., Harris, S., …Williams, D. (2022). Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19. Diabetes Care, 45(12), 2838-2843. https://doi.org/10.2337/dc22-0357

OBJECTIVE
To determine the association between prescription of SGLT2 inhibitors (SGLT2is) and diabetic ketoacidosis (DKA) incidence or mortality in people with type 2 diabetes (T2D) hospitalized with COVID-19.

RESEARCH DESIGN AND METHODS
This... Read More about Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice (2022)
Journal Article
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., Amiel, S. A., Bally, L., Beck, R. W., Biester, S., Biester, T., Blanchette, J. E., Bosi, E., Boughton, C. K., Breton, M. D., Brown, S. A., …Battelino, T. (2023). Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews, 44(2), 254-280. https://doi.org/10.1210/endrev/bnac022

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long... Read More about Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.

Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study (2021)
Journal Article
Wilmot, E. G., Close, K. L., Jurišić‐Eržen, D., Bruttomesso, D., Ampudia‐Blasco, F. J., Bosnyak, Z., Roborel de Climens, A., Bigot, G., Peters, A. L., Renard, E., Berard, L., Calliari, L. E., & Seufert, J. (2021). Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study. Diabetes, Obesity and Metabolism, 23(8), 1892-1901. https://doi.org/10.1111/dom.14416

Aims
To conduct a secondary analysis of the SAGE study to evaluate the association between glycaemic control and patient-reported outcomes (PROs), in adults with type 1 diabetes (T1DM) across different age groups and regions.

Materials and metho... Read More about Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study.

Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of british clinical diabetologists (Abcd) nationwide audit (2020)
Journal Article
Deshmukh, H., Wilmot, E. G., Gregory, R., Barnes, D., Narendran, P., Saunders, S., Furlong, N., Kamaruddin, S., Banatwalla, R., Herring, R., Kilvert, A., Patmore, J., Walton, C., Ryder, R. E., & Sathyapalan, T. (2020). Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of british clinical diabetologists (Abcd) nationwide audit. Diabetes Care, 43(9), 2153-2160. https://doi.org/10.2337/dc20-0738

OBJECTIVE

The FreeStyle Libre (FSL) flash glucose-monitoring device was made available on the U.K. National Health Service (NHS) drug tariff in 2017. This study aims to explore the U.K. real-world experience of FSL and the impact on glycemic contr... Read More about Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of british clinical diabetologists (Abcd) nationwide audit.